VJVirtual | Future indications for MRx0518

Alex Stevenson, PhD, 4D Pharma plc, Leeds, UK, reflects on the positive interim results in evaluating MRx0518 and pembrolizumab combination therapy in patients with secondary resistance to pembrolizumab showing evidence of previous checkpoint therapy reactivation with MRx0518 (NCT03637803). The study is being conducted on a treatment resistant population with a median of three unsuccessful prior therapies. Dr Stevenson hopes that MRx0518 will show similar success with different checkpoint therapies earlier in patient treatment regimens and highlights an ongoing study of MRx0518 in combination with avelumab as a first-line maintenance therapy for urothelial carcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).